New CAR T-cell therapy targeting B cells for lupus treatment
Allogeneic BAFF Ligand Based CAR T-Cells as a Novel Therapy for Systemic Lupus Erythematous
This study is testing a new type of CAR T-cell therapy designed to help people with systemic lupus erythematosus (SLE) by targeting and removing the harmful B cells that contribute to the disease, with the hope of improving treatment outcomes and safety.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Luminary Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10761003 on NIH RePORTER |
What this research studies
This research investigates a novel therapy for systemic lupus erythematosus (SLE) using allogeneic BAFF ligand-based CAR T-cells. The approach aims to eliminate autoreactive B cells, which are key drivers of SLE, by utilizing a new type of CAR T-cell that targets specific receptors on these cells. The study builds on previous findings that showed promise in B cell clearance and disease remission, but seeks to improve upon existing therapies by addressing limitations in targeting long-lived plasma cells. Patients may be monitored for biomarkers to assess treatment efficacy and safety.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with systemic lupus erythematosus, particularly those with active disease and high levels of autoreactive B cells.
Not a fit: Patients who do not have systemic lupus erythematosus or those with other autoimmune diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, more effective treatment option for patients with systemic lupus erythematosus.
How similar studies have performed: Previous research has shown success with CAR T-cell therapies in other autoimmune conditions, indicating potential for this novel approach in lupus treatment.
Where this research is happening
Minneapolis, United States
- Luminary Therapeutics, INC. — Minneapolis, United States (Active)
Researchers
- Principal investigator: Gibbons, Hunter Ramsdell — Luminary Therapeutics, INC.
- Study coordinator: Gibbons, Hunter Ramsdell
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.